What changed
Intellia Therapeutics entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed. The facility includes an initial term loan of $75 million funded at closing, up to $225 million across 5 additional tranches tied primarily to lonvo-z milestones, and an additional $100 million available subject to mutual agreement during the five-year term. The financing supports a planned U.S. approval and commercial launch of lonvoguran ziclumeran for hereditary angioedema.
Why it matters
Intellia Therapeutics entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed. The facility includes an initial term loan of $75 million funded at closing, up to $225 m
← Dashboard
Sep 24, 2026 09:14 PM ET